OIPE JC
JAN 03 2005
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → ☑

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/680,275
Filing Date	10-08-03
First Named Inventor	LANG
Group Art Unit	1617
Examiner Name	Theodore J. Criares
Attorney Docket Number	DEAV1996/F140 - US - CNT - 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature	/Leonard Williams/ (07/09/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☑

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/680,275
Filing Date	10-08-03
First Named Inventor	LANG
Group Art Unit	1617
Examiner Name	Theodore J. Criares
Attorney Docket Number	DEAV1996/F140 - US - CNT - 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
/LW/		M. BAUMGARTH et al., (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ Antiporter Inhibitors, J. Med. Chem 1997, Vol. 40, 1997, pp. 2017-2034	

Examiner Signature	/Leonard Williams/ (07/09/2007)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.: 02481.1622-02	Application No.: Not Yet Assigned
Applicant: Hans Jochen LANG et al.	
Filing Date: October 8, 2003	Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
/LW/		5,110,817	5/1992	K.H. Beyer, Jr.			
/LW/		5,132,324	7/1992	M.D. Meglasson			
/LW/		5,234,946	8/1993	Takezawa et al.			
/LW/		5,292,755	3/1994	Englert et al.			
/LW/		5,416,094	5/1995	Lal et al.			
/LW/		5,719,169	2/1998	H.W. Kleemann et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
/LW/		EP 0 612 723	8/1994	EUROPE (w/Derwent Abstract)			(Abstract)
/LW/		EP 0 627 413	12/1994	EUROPE (w/Derwent Abstract)			(Abstract)
/LW/		EP 0 640 593	3/1995	EUROPE (w/Derwent Abstract			(Abstract)
/LW/		WO 96/00725	1/1996	WIPO			
/LW/		WO 96/04241	2/1996	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/LW/		Matthias Barton, et al., "Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis", *Journal of the American Society of Nephrology*, Vol. 11(5):835-846 (2000).

Examiner /Leonard Williams/ (07/09/2007)	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.: 02481.1622-02	Application No.: Not Yet Assigned
Applicant: Hans Jochen LANG et al.	
Filing Date: October 8, 2003	Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/LW/		Martina B. Britten et al., "Endothelial function and exercise", *Dtsch. Z. Sportmed*, Vol. 51(4):118-122, Abstract (2000).
/LW/		Stephen J. Cleland, et al., "Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease", *Clinical Science*, Vol. 98(5):531-535 (2000).
/LW/		F. Contreraras, et al., "Endothelial dysfunction in arterial hypertension", *Journal of Human Hypertension*, Vol. 14(Suppl. 1):S20-S25 (2000).
/LW/		Philip A. MacCarthy, et al., "Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy", *Circulation, Journal of the American Heart Association*, Vol. 101(15):1854-1860 (2000).
/LW/		Scott T.W. Morris et al., "Endothelial dysfunction in renal transplant recipients maintained on cyclosporine", *Kidney International*, Vo. 57(3):1091-1099 (2000).
/LW/		Jerry-Roch Nofer et al., "Low-Density Lipoproteins Inhibit the Na+/H+ Antiport in Human Platelets", *Circulation*, Vol 95(6):1370-1376 (March 18, 1997).
/LW/		Bruno Pannier, et al., "Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in en-stage renal disease", *Kidney International*, Vol. 57(3):1091-1099 (2000).
/LW/		Ernesto L. Schriffin, et al., "Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan", *Circulation, Journal of the American Heart Association*, Vol. 101(4):1653-1659 (2000).

Examiner /Leonard Williams/ (07/09/2007)	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.: 02481.1622-02	Application No.: Not Yet Assigned
Applicant: Hans Jochen LANG et al.	
Filing Date: October 8, 2003	Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/LW/		J. Schneider, "Effects of a Furosemide-amiloride Combination on Plasma Lipoproteins in Patients with Mild to Moderate Hypertension and Preexisting Hyperlipoproteinemia", *Current Therapeutic Research*, Vol 47(1):239-244 (January 1, 1990).
/LW/		W. Scholz et al., "Effects of Na+/H+ Exchange Inhibitors in Cardiac Ischemia", *Academic Press Limited*, pp 731-739 (1992).
/LW/		Toshiyuki Tamagaki et al., "Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells", *Atherosclerosis*, Vol 123, pp 73-82 (1996).
/LW/		Paul Vanhoutte, et al., "Endothelial function and dysfunction", *Basic Science for the Cardiologist, Biology of the Arterial Wall*, pp. 49-70 (1999).
/LW/		Agostino Virdis, et al., "Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women", *Circulation, Journal of the American Heart Association*, Vol. 101(19):2258-2263 (2000).

Examiner /Leonard Williams/ (07/09/2007)	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 - Patent and Trademark Office - U.S. Department of Commerce